Table 3 Spleen tyrosine kinase inhibition therapy in allergic inflammatory disease models

Seow et al. [40]

Piceatannol

In vitro

Ovalbumin-induced anaphylaxis in guinea pig

Prevented histamin and leukotriene release

Guyer et al. [54]

R112

One dose, intranasally

Drug safety study in volunteers with allergic rhinitis

Drug is safe, reduced PGD2, no differences in symptoms

Matsubara et al. [20]

R406

10 days, 5 mL/kg, twice a day, orally

Animal allergic asthma in BALB/c mice

Decreased pulmonary eosinophilia and AHR

Matsubara et al. [22]

R406

5 days, 30 mg/kg, twice a day, orally

AHR in BALB/c mice

Protected from AHR, eosinophilia, and lymphocytosis

Meltzer et al. [39]

R112

2 days, intranasally

Human seasonal allergic rhinitis

Improved global clinical symptoms

Yamamoto et al. [41]

BAY 61-3606

21 days, twice a day, orally

Antigen induced airway inflammation in rodents

Suppressed antigen-induced passive cutaneous reaction, bronchoconstriction, bronchial edema, and airway inflammation.